AR102594A1 - ANTICUERPOS ANTI-IL-1b Y MÉTODOS DE USO - Google Patents
ANTICUERPOS ANTI-IL-1b Y MÉTODOS DE USOInfo
- Publication number
- AR102594A1 AR102594A1 ARP150103647A ARP150103647A AR102594A1 AR 102594 A1 AR102594 A1 AR 102594A1 AR P150103647 A ARP150103647 A AR P150103647A AR P150103647 A ARP150103647 A AR P150103647A AR 102594 A1 AR102594 A1 AR 102594A1
- Authority
- AR
- Argentina
- Prior art keywords
- amino acid
- hvr
- seq
- acid sequence
- acid residue
- Prior art date
Links
- 150000001413 amino acids Chemical group 0.000 abstract 6
- 125000000539 amino acid group Chemical group 0.000 abstract 4
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 abstract 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 abstract 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 abstract 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 abstract 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 abstract 1
- 208000014245 Ocular vascular disease Diseases 0.000 abstract 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 abstract 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 abstract 1
- 235000004279 alanine Nutrition 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 229960000310 isoleucine Drugs 0.000 abstract 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 abstract 1
- 208000002780 macular degeneration Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 abstract 1
- 239000004474 valine Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/245—IL-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Ophthalmology & Optometry (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Reivindicación 1: Un anticuerpo humanizado que se une específicamente a IL-1b humana y de cinomolgo, en el que el anticuerpo humanizado comprende (a) una HVR-H1 que comprende la secuencia de aminoácidos de SEC ID Nº 25, (b) una HVR-H2 que comprende la secuencia de aminoácidos de SEC ID Nº 26, (c) una HVR-H3 que comprende la secuencia de aminoácidos de SEC ID Nº 28, (d) una HVR-L1 que comprende la secuencia de aminoácidos de SEC ID Nº 15, (e) una HVR-L2 que comprende la secuencia de aminoácidos de SEC ID Nº 16, y (f) HVR-L3 que comprende la secuencia de aminoácidos de SEC ID Nº 17, en el que en el dominio variable de la cadena pesada en la posición 48 es un resto de aminoácido de isoleucina, en la posición 67 es un resto de aminoácido de alanina, en la posición 69 es un resto de aminoácido de fenilalanina y en la posición 93 es un resto de aminoácido de valina y en el dominio variable de cadena ligera en la posición 36 es el resto de aminoácido serina (numeración según Kabat). Reivindicación 6: Una formulación farmacéutica que comprende un anticuerpo de acuerdo con una cualquiera de las reivindicaciones 1 a 5 y opcionalmente un vehículo farmacéuticamente aceptable. Reivindicación 10: El uso de acuerdo con una cualquiera de las reivindicaciones 8 y 9, en el que el medicamento es para el tratamiento de una enfermedad vascular ocular, preferentemente para el tratamiento de la degeneración macular.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14192523 | 2014-11-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR102594A1 true AR102594A1 (es) | 2017-03-08 |
Family
ID=51868114
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP150103647A AR102594A1 (es) | 2014-11-10 | 2015-11-09 | ANTICUERPOS ANTI-IL-1b Y MÉTODOS DE USO |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US10344085B2 (es) |
| EP (1) | EP3218402A1 (es) |
| JP (1) | JP6787888B2 (es) |
| KR (1) | KR20170081253A (es) |
| CN (1) | CN107074942A (es) |
| AR (1) | AR102594A1 (es) |
| AU (1) | AU2015345320A1 (es) |
| BR (1) | BR112017009817A2 (es) |
| CA (1) | CA2963719A1 (es) |
| IL (1) | IL251165A0 (es) |
| MX (1) | MX2017005987A (es) |
| RU (1) | RU2017120358A (es) |
| SG (1) | SG11201702550WA (es) |
| TW (1) | TW201632552A (es) |
| WO (1) | WO2016075034A1 (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2417156E (pt) | 2009-04-07 | 2015-04-29 | Roche Glycart Ag | Anticorpos trivalentes, biespecíficos |
| KR20170082594A (ko) | 2014-11-10 | 2017-07-14 | 에프. 호프만-라 로슈 아게 | 항-ang2 항체 및 사용 방법 |
| KR20170081253A (ko) | 2014-11-10 | 2017-07-11 | 에프. 호프만-라 로슈 아게 | 항-il-1베타 항체 및 이의 사용 방법 |
| CN107074941A (zh) | 2014-11-10 | 2017-08-18 | 豪夫迈·罗氏有限公司 | 双特异性抗体和用于眼科学的方法 |
| MX2017005975A (es) | 2014-11-10 | 2017-06-29 | Hoffmann La Roche | Anticuerpos anti factor de crecimiento derivado de plaquetas b (pdgf-b) y metodos de uso. |
| ES2764111T3 (es) | 2014-12-03 | 2020-06-02 | Hoffmann La Roche | Anticuerpos multiespecíficos |
| WO2018212556A1 (en) * | 2017-05-16 | 2018-11-22 | Cj Healthcare Corporation | A method for purifying an antibody or an antibody fragment thereof using affinity chromatography |
| AR111761A1 (es) * | 2017-05-16 | 2019-08-14 | Cj Healthcare Corp | Un método para purificar un anticuerpo o un fragmento de anticuerpo de este usando cromatografía de afinidad |
| EP3638697A4 (en) | 2017-06-12 | 2021-07-07 | Bluefin Biomedicine, Inc. | ANTI-IL1RAP ANTIBODIES AND ANTIBODY INGREDIENT CONJUGATES |
| MX2020007882A (es) * | 2018-01-26 | 2020-12-03 | Genzyme Corp | Variantes fc con unión mejorada a fcrn y semivida prolongada. |
| CN110818793A (zh) | 2018-08-14 | 2020-02-21 | 中山康方生物医药有限公司 | 抗IL-1β的抗体、其药物组合物及其用途 |
| KR20240042566A (ko) * | 2018-12-21 | 2024-04-02 | 에프. 호프만-라 로슈 아게 | Vegf 및 il-1베타에 결합하는 항체 및 이의 사용 방법 |
| CN117024587A (zh) * | 2019-03-07 | 2023-11-10 | 瑞阳(苏州)生物科技有限公司 | 人IL-1β蛋白结合分子及其编码基因和应用 |
| US11851499B2 (en) | 2019-06-11 | 2023-12-26 | Bioatla, Inc. | Conditionally active anti-EpCAM antibodies, antibody fragments, their immunoconjugates and uses thereof |
| CN114524875B (zh) * | 2021-11-11 | 2023-07-25 | 江苏莱森生物科技研究院有限公司 | 偶联IL-1β单克隆抗体的纳米硅球及应用 |
| CN117126278B (zh) * | 2023-10-26 | 2024-01-05 | 中国科学院苏州纳米技术与纳米仿生研究所 | 一种单克隆抗体及其应用 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4935343A (en) * | 1986-08-08 | 1990-06-19 | Syntex (U.S.A.) Inc. | Monoclonal antibodies for interleukin-1β |
| AU2003208946A1 (en) * | 2002-02-28 | 2003-09-16 | Eli Lilly And Company | Anti-interleukin-1 beta analogs |
| EP1600459A3 (en) | 2002-06-28 | 2005-12-07 | Domantis Limited | Ligand |
| US7541033B2 (en) * | 2003-01-24 | 2009-06-02 | Applied Molecular Evolution, Inc. | Humanized anti-IL-1β antibodies |
| WO2005052002A2 (en) * | 2003-11-20 | 2005-06-09 | Massachusetts Institute Of Technology | Single-domain antibodies and uses thereof |
| WO2005087812A1 (en) | 2004-03-05 | 2005-09-22 | Ludwig Institute For Cancer Research | Multivalent antibody materials and methods for vegf/pdgf family of growth factors |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| US8268314B2 (en) | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
| TW201031421A (en) * | 2009-01-29 | 2010-09-01 | Abbott Lab | IL-1 binding proteins |
| AU2010306681A1 (en) * | 2009-10-15 | 2012-04-19 | Abbvie Inc. | IL-1 binding proteins |
| AR080794A1 (es) | 2010-03-26 | 2012-05-09 | Hoffmann La Roche | Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2 |
| KR20130100125A (ko) * | 2010-08-13 | 2013-09-09 | 제넨테크, 인크. | 질환의 치료를 위한, ＩＬ-1β 및 ＩＬ-18에 대한 항체 |
| NZ607510A (en) * | 2010-09-10 | 2014-10-31 | Apexigen Inc | Anti-il-1 beta antibodies and methods of use |
| AU2011361720B2 (en) * | 2010-12-21 | 2017-04-27 | Abbvie Inc. | IL-1 -alpha and -beta bispecific dual variable domain immunoglobulins and their use |
| US9151761B2 (en) | 2011-06-29 | 2015-10-06 | Amgen Inc. | Predictive biomarker of survival in the treatment of renal cell carcinoma |
| EP2867360B1 (en) | 2012-06-28 | 2019-05-08 | Molecular Partners AG | Designed ankyrin repeat proteins binding to platelet-derived growth factor |
| RS62509B1 (sr) | 2012-07-13 | 2021-11-30 | Roche Glycart Ag | Bispecifična anti-vegf/anti-ang-2 antitela i njihova upotreba u lečenju očnih vaskularnih bolesti |
| CA2883807A1 (en) | 2012-09-28 | 2014-04-03 | Boehringer Ingelheim International Gmbh | Pharmaceutical combinations comprising dual angiopoietin-2 / dll4 binders and anti-vegf-r agents |
| KR20150060686A (ko) | 2012-09-28 | 2015-06-03 | 베링거 인겔하임 인터내셔날 게엠베하 | 이중 안지오포이에틴-2/Dll4 결합제 및 항-VEGF 제제를 포함하는 약제학적 조합물 |
| MX389676B (es) | 2012-11-08 | 2025-03-20 | Clearside Biomedical Inc | Metodos y dispositivos para el tratamiento de trastornos oculares en sujetos humanos |
| CN105026426A (zh) | 2012-11-09 | 2015-11-04 | 辉瑞公司 | 血小板衍生生长因子b之特异性抗体及其组合物和用途 |
| JO3405B1 (ar) | 2013-01-09 | 2019-10-20 | Regeneron Pharma | الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها |
| EP2970459A2 (en) * | 2013-03-15 | 2016-01-20 | AbbVie Inc. | Dual specific binding proteins directed against il-1beta and il-17 |
| AU2014261630B2 (en) * | 2013-04-29 | 2019-05-09 | F. Hoffmann-La Roche Ag | Human FcRn-binding modified antibodies and methods of use |
| BR112016007112A2 (pt) | 2013-12-20 | 2017-09-19 | Hoffmann La Roche | Anticorpos que se ligam a angiopoietina 2 (ang-2) humana, usos de um anticorpo que se liga a angiopoietina 2 (ang-2) humana e combinação |
| MX382848B (es) | 2014-01-15 | 2025-03-13 | Hoffmann La Roche | Variantes de región fc con propiedades de unión a receptor fc neonatal (fcrn) modificadas y de unión a proteína a mantenidas. |
| KR20170082594A (ko) | 2014-11-10 | 2017-07-14 | 에프. 호프만-라 로슈 아게 | 항-ang2 항체 및 사용 방법 |
| KR20170081253A (ko) | 2014-11-10 | 2017-07-11 | 에프. 호프만-라 로슈 아게 | 항-il-1베타 항체 및 이의 사용 방법 |
| CN107074941A (zh) | 2014-11-10 | 2017-08-18 | 豪夫迈·罗氏有限公司 | 双特异性抗体和用于眼科学的方法 |
| MX2017005975A (es) | 2014-11-10 | 2017-06-29 | Hoffmann La Roche | Anticuerpos anti factor de crecimiento derivado de plaquetas b (pdgf-b) y metodos de uso. |
| WO2016209972A1 (en) | 2015-06-26 | 2016-12-29 | Amgen Inc. | Biomarker of survival in the treatment of renal cell carcinoma with a vegfr inhibitor and an ang2 inhibitor |
| CN110691790A (zh) | 2017-06-02 | 2020-01-14 | 勃林格殷格翰国际有限公司 | 抗癌联合治疗 |
-
2015
- 2015-11-06 KR KR1020177015590A patent/KR20170081253A/ko not_active Withdrawn
- 2015-11-06 CN CN201580060880.4A patent/CN107074942A/zh active Pending
- 2015-11-06 WO PCT/EP2015/075875 patent/WO2016075034A1/en not_active Ceased
- 2015-11-06 JP JP2017525023A patent/JP6787888B2/ja not_active Expired - Fee Related
- 2015-11-06 CA CA2963719A patent/CA2963719A1/en not_active Abandoned
- 2015-11-06 AU AU2015345320A patent/AU2015345320A1/en not_active Abandoned
- 2015-11-06 MX MX2017005987A patent/MX2017005987A/es unknown
- 2015-11-06 RU RU2017120358A patent/RU2017120358A/ru not_active Application Discontinuation
- 2015-11-06 EP EP15790945.8A patent/EP3218402A1/en not_active Withdrawn
- 2015-11-06 SG SG11201702550WA patent/SG11201702550WA/en unknown
- 2015-11-06 BR BR112017009817A patent/BR112017009817A2/pt not_active Application Discontinuation
- 2015-11-09 TW TW104136907A patent/TW201632552A/zh unknown
- 2015-11-09 AR ARP150103647A patent/AR102594A1/es unknown
-
2017
- 2017-03-14 IL IL251165A patent/IL251165A0/en unknown
- 2017-05-09 US US15/590,161 patent/US10344085B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| RU2017120358A3 (es) | 2019-05-29 |
| IL251165A0 (en) | 2017-04-30 |
| CN107074942A (zh) | 2017-08-18 |
| MX2017005987A (es) | 2017-06-29 |
| EP3218402A1 (en) | 2017-09-20 |
| AU2015345320A1 (en) | 2017-04-06 |
| BR112017009817A2 (pt) | 2018-02-14 |
| CA2963719A1 (en) | 2016-05-19 |
| JP2017534646A (ja) | 2017-11-24 |
| US10344085B2 (en) | 2019-07-09 |
| US20170247447A1 (en) | 2017-08-31 |
| TW201632552A (zh) | 2016-09-16 |
| RU2017120358A (ru) | 2018-12-13 |
| KR20170081253A (ko) | 2017-07-11 |
| WO2016075034A1 (en) | 2016-05-19 |
| SG11201702550WA (en) | 2017-04-27 |
| JP6787888B2 (ja) | 2020-11-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR102594A1 (es) | ANTICUERPOS ANTI-IL-1b Y MÉTODOS DE USO | |
| AR102592A1 (es) | Anticuerpos biespecíficos y métodos de uso en oftalmología | |
| AR102593A1 (es) | Anticuerpos anti-pdgf-b y métodos de uso | |
| PE20161571A1 (es) | Anticuerpos anti-ox40 y metodos de uso | |
| PE20212088A1 (es) | Anticuerpos anti-tau y uso de los mismos | |
| JP2020500538A5 (es) | ||
| ES2685424T3 (es) | Anticuerpos anti-Jagged1 y procedimientos de uso | |
| PE20150025A1 (es) | Anticuerpos e inmunoconjugados contra ly6e y metodos de uso | |
| PE20170935A1 (es) | Anticuerpos anti-her2 e inmunoconjugados | |
| AR106991A1 (es) | Anticuerpos neutralizantes del virus de inmunodeficiencia humana | |
| AR091701A1 (es) | Anticuerpos anti-cd22 e inmunoconjugados | |
| AR086044A1 (es) | Anticuerpos que se unen especificamente a un dominio extracelular de c-kit y usos de los mismos | |
| HRP20200767T1 (hr) | Humanizirana anti-humana cd19 protutijela i postupci uporabe | |
| PE20181270A1 (es) | Anticuerpo que neutraliza el virus respiratorio sincitial humano | |
| PE20201186A1 (es) | Anticuerpos antitau y metodos de uso | |
| PE20170953A1 (es) | ANTICUERPOS ANTI-CD79b Y METODOS DE USO | |
| PE20150614A1 (es) | Inmunoconjugados que comprenden un anticuerpo anti-cd79b ligado a un derivado de nemorrubicina | |
| PE20220487A1 (es) | Anticuerpos anti-ms4a4a y metodos de uso de los mismos | |
| PE20161376A1 (es) | Anticuerpos de hemaglutinina contra el virus de la influenza b y metodos de uso | |
| PE20161245A1 (es) | Anticuerpos especificos del receptor del factor 1 de crecimiento similar a la insulina y usos de los mismos | |
| JP2018507220A5 (es) | ||
| PE20141562A1 (es) | Anticuerpos anti-htra1 y metodos de uso | |
| PE20190733A1 (es) | Anticuerpos contra el virus del dengue, polipeptidos que contienen regiones fc variantes, y metodos de uso | |
| AR103713A1 (es) | Anticuerpos contra tau y sus usos | |
| PE20161311A1 (es) | Anticuerpos especificos del receptor del factor 1 de crecimiento similar a la insulina y usos de los mismos. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |